I initially rated Aurinia Pharmaceuticals a "Sell" in February 2024, but the stock has since risen over 25%, proving my call incorrect. Lupkynis, Aurinia's sole commercial product, showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback